New Experimental Blood Test Detects Four Major Conditions Within One Hour
Researchers at the University of Notre Dame have developed an experimental blood screening platform capable of identifying early markers for colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer's disease in about an hour.
🧠AI AnalysisPhoto: Medical Xpress
Key points
- Notre Dame researchers developed a rapid blood test for four major diseases.
- The method achieved 90% to 99% accuracy in a blind study of 87 plasma samples.
- The platform detects disease-specific proteins on exosomes using specialized Janus particles.
A research team led by Hsueh-Chia Chang at the University of Notre Dame has created a diagnostic platform that uses a small blood sample to screen for four severe conditions: colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer's disease. Published in Nature Biomedical Engineering, the technology relies on detecting blood-borne exosomes, which are microscopic vesicles that carry proteins serving as early indicators of illness.
During a blind evaluation using 87 plasma samples from both healthy individuals and patients diagnosed with one of the target conditions, the platform demonstrated an accuracy rate ranging from 90% to 99%. The test requires just 10 microliters of blood diluted in saline, mixed with specialized dual-sided particles called immunojanus spheres for up to an hour, and analyzed using a proprietary computer program.
While the initial results suggest high sensitivity and selectivity, experts note that the findings stem from a relatively small, early-stage blind test. Further clinical validation with larger, diverse patient populations is necessary before this technology can be widely adopted in clinical settings. Patients should consult qualified medical professionals for any health-related screening and diagnostic decisions.
What to know
- Technology: Uses immunojanus particles to capture and signal disease-specific exosome proteins.
- Speed and Sample: Requires 10 microliters of blood and provides results in an hour.
- Scope: Evaluated for colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer's disease.
Source Medical Xpress — medicalxpress.com/news/2026-11-experimental-blood-deadly-diseases-hour.… ↗
Read next
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …